HALO Halozyme Therapeutics Inc.

-0.39  -2%
Previous Close 16.36
Open 16.33
Price To Book 9.34
Market Cap 2320449528
Shares 145,300,534
Volume 1,062,740
Short Ratio
Av. Daily Volume 798,681

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
Pancreatic cancer
Approved September 12, 2014.
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.
PEGPH20 and atezolizumab
Phase 1b/2 open label trial ongoing - noted January 9, 2019.
PEGPH20 and atezolizumab
Pancreatic cancer
FDA approval announced February 28, 2019.
Trastuzumab (Herceptin) using ENHANZE
Breast cancer
Regulatory filing due 2H 2019.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma

Latest News

  1. Need To Know: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Insiders Have Been Selling Shares
  2. 3 Cancer Treatment Stocks to Buy in March
  3. 2 Stocks You Definitely Should Consider Shorting This Week
  4. Top Ranked Momentum Stocks to Buy for March 4th
  5. Halozyme To Participate In Upcoming Investor Conferences
  6. Halozyme Announces FDA Approval Of Herceptin Hylecta™
  7. Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript
  8. Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
  9. Halozyme Therapeutics: 4Q Earnings Snapshot
  10. Halozyme Reports Fourth Quarter And Full-Year 2018 Results
  11. The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
  12. Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications
  13. Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
  14. Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) CEO Pay Fair?
  15. See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
  16. Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call
  17. Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
  18. argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
  19. Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
  20. Alexion's Ultomiris Meets Primary Endpoint in aHUS Study